- Conditions
- Retinal Detachment, Rhegmatogenous Retinal Detachment
- Interventions
- Lamivudine 300 MG, Placebo
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–16
of 16
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Retinal Detachment, Full Thickness Macular Hole, Epiretinal Membrane
- Interventions
- Pars plana vitrectomy, External drainage
- Procedure
- Lead sponsor
- Allen C. Ho, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Epiretinal Membrane, Macular Hole, Visually Significant Vitreous Floater, Vitreomacular Traction, Vitreous Hemorrhage, Proliferative Diabetic Retinopathy, Rhegmatogenous Retinal Detachment, Retained Lens Material in the Posterior Segment
- Interventions
- UNITY Vitreoretinal Cataract System (VCS), CONSTELLATION Vision System, Vitreoretinal ophthalmic surgery
- Device · Procedure
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 8
- States / cities
- Scottsdale, Arizona • Laguna Hills, California • West Des Moines, Iowa + 5 more
- Conditions
- Vitreoretinopathy, Coats' Disease, Exudative Retinopathy, Lattice Degeneration, Retinal Hole, Sickler's Syndrome, Retinal Detachment Rhegmatogenous, Retinal Detachment Exudative, Retinal Detachment Traction
- Interventions
- Dextenza 0.4Mg Ophthalmic Insert, Pred Forte
- Drug
- Lead sponsor
- Lejla Vajzovic, MD, FASRS
- Other
- Eligibility
- 3 Years to 17 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Retina; Detachment, Rhegmatogenous
- Interventions
- Retina re-attachment repair using C3F8 gas tamponade
- Device
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 1
- States / cities
- Prairie Village, Kansas
- Conditions
- Rhegmatogenous Retinal Detachment - Macula Off
- Interventions
- ONL1204 Ophthalmic Solution, Sham treatment
- Drug
- Lead sponsor
- ONL Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 36
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 32 more
- Conditions
- Retinal Detachment
- Interventions
- Retinal Detachment repair
- Procedure
- Lead sponsor
- Wills Eye
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Traction Retinal Detachments, Rhegmatogenous Retinal Detachments, Dislocated Intraocular Lens
- Interventions
- Intraocular assistance
- Procedure
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Rhegmatogenous Retinal Detachment
- Interventions
- Pars plana vitrectomy, Triamcinolone Acetonide 40mg/mL, Moxifloxacin 0.5% or Polymyxin/Trimethoprim if patient is allergic to moxifloxacin, Prednisolone 1%, Atropine 1%
- Procedure · Drug
- Lead sponsor
- Massachusetts Eye and Ear Infirmary
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 168 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Rhegmatogenous Retinal Detachment, Proliferative Vitreoretinopathy
- Interventions
- Netarsudil Ophthalmic
- Drug
- Lead sponsor
- Massachusetts Eye and Ear Infirmary
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Proliferative Vitreoretinopathy, Rhegmatogenous Retinal Detachment
- Interventions
- Methotrexate Injection, Methotrexate Infusion, Sham Injection
- Drug
- Lead sponsor
- Cincinnati Eye Institute, Southwest Ohio
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 860 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Rhegmatogenous Retinal Detachment, Proliferative Vitreoretinopathy
- Interventions
- Netarsudil 0.02% Ophthalmic Solution [RHOPRESSA], Glycerin 0.2%/Hypromellose 0.2%/Peg 1%/Soln,Oph,Ud
- Drug
- Lead sponsor
- Wills Eye
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Proliferative Vitreoretinopathy
- Interventions
- Methotrexate
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- Up to 18 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Rhegmatogenous Macula-off Retinal Detachment
- Interventions
- 400 ug Brimonidine Implant, 200 ug Brimonidine Implant, Sham (no implant)
- Drug · Other
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Abilene, Texas
- Conditions
- Retinal Detachment With Multiple Breaks, Unspecified Eye, Proliferative Vitreoretinopathy
- Interventions
- Intravitreal aflibercept injection, Sham control
- Drug · Other
- Lead sponsor
- M. Ali Khan, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Retinal Detachment
- Interventions
- denufosol tetrasodium (INS37217) Intravitreal Injection
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 33
- States / cities
- Tucson, Arizona • Beverly Hills, California • Los Angeles, California + 29 more